Status:
UNKNOWN
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
Lead Sponsor:
Cancer Research UK
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividin...
Detailed Description
OBJECTIVES: Primary * Determine the response rate in patients with angioimmunoblastic T-cell lymphoma after chemotherapy comprising fludarabine and cyclophosphamide. Secondary * Assess the increme...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Newly diagnosed angioimmunoblastic T-cell lymphoma
- Measurable disease (i.e., anatomically assessable)
- PATIENT CHARACTERISTICS:
- WHO/ECOG performance status 0-2
- Serum creatinine ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception before, during, and after study treatment
- No known seropositivity for hepatitis B virus, hepatitis C virus, or HIV
- No active second malignancy or other concomitant serious medical condition, in particular peripheral neuropathy
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for angioimmunoblastic T-cell lymphoma
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00958854
Start Date
January 1 2006
Last Update
August 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Research UK and University College London Cancer Trials Centre
Exeter, England, United Kingdom, EX2 5DW